Literature DB >> 31112944

Psychosocial Impact of Dysarthria: The Patient-Reported Outcome as Part of the Clinical Management.

Cyril Atkinson-Clement1, Alban Letanneux2, Guillaume Baille3, Marie-Charlotte Cuartero4, Lauriane Véron-Delor4,5, Camille Robieux4, Manon Berthelot4, Danièle Robert4,6, Jean-Philippe Azulay7,8, Luc Defebvre3, Joaquim Ferreira9, Alexandre Eusebio7,8, Caroline Moreau3, Serge Pinto4.   

Abstract

BACKGROUND: Dysarthria in neurological disorders can have psychosocial consequences. The dysarthric speaker's perspective towards the disorder's psychosocial impact is essential in its global assessment and management. For such purposes, assessment tools such as the Dysarthria Impact Profile (DIP) are indispensable.
OBJECTIVE: We aimed to confirm the relevance of using the DIP to quantify the psychosocial consequences of dysarthria in neurological diseases.
METHODS: We studied 120 participants, 15 healthy controls and 105 patients with different kinds of dysarthria induced by several neurological disorders (Parkinson's disease [PD], Huntington's disease, dystonia, cerebellar ataxia, progressive supranuclear palsy [PSP], multiple system atrophy, lateral amyotrophic sclerosis). All participants underwent a cognitive evaluation and a speech intelligibility assessment and completed three self-reported questionnaires: the 36-Item Short Form Health Survey, the Voice Handicap Index (VHI), and the DIP.
RESULTS: The psychometric properties of the DIP were confirmed, including internal consistency (α = 0.93), concurrent validity (correlation with the VHI: r = -0.77), and discriminant validity (accuracy = 0.93). Psychosocial impact of dysarthria was revealed by the DIP for all patients. Intelligibility loss was found strongly correlated with the psychosocial impact of dysarthria: for a similar level of intelligibility impairment, the DIP total score was similar regardless of the pathological group. However, our findings suggest that the psychosocial impact measured by the DIP could be partially independent from the severity of dysarthria (indirectly addressed here via speech intelligibility): the DIP was able to detect patients without any intelligibility impairment, but with a psychosocial impact.
CONCLUSIONS: All patients reported a communication complaint, attested by the DIP scores, despite the fact that not all patients, notably PD, ataxic, and PSP patients, had an intelligibility deficit. The DIP should be used in clinical practice to contribute to a holistic evaluation and management of functional communication in patients with dysarthria.
© 2019 S. Karger AG, Basel.

Entities:  

Keywords:  Dysarthria; Psychosocial impact; Self-assessment; Speech; Voice

Year:  2019        PMID: 31112944     DOI: 10.1159/000499627

Source DB:  PubMed          Journal:  Neurodegener Dis        ISSN: 1660-2854            Impact factor:   2.977


  4 in total

Review 1.  Social Symptoms of Parkinson's Disease.

Authors:  Margaret T M Prenger; Racheal Madray; Kathryne Van Hedger; Mimma Anello; Penny A MacDonald
Journal:  Parkinsons Dis       Date:  2020-12-31

2.  Subthalamic stimulation breaks the balance between distal and axial signs in Parkinson's disease.

Authors:  Cyril Atkinson-Clement; Émilie Cavazzini; Alexandre Zénon; Thierry Legou; Tatiana Witjas; Frédérique Fluchère; Jean-Philippe Azulay; Christelle Baunez; Serge Pinto; Alexandre Eusebio
Journal:  Sci Rep       Date:  2021-11-08       Impact factor: 4.379

3.  The Impact of PD Check-In, a Model for Supported Self-Managed Maintenance of Speech on the Quality of Life of People with Parkinson's Disease: A Phase 1 Study.

Authors:  Ann Finnimore; Deborah Theodoros; Anna Rumbach
Journal:  Brain Sci       Date:  2022-03-24

4.  Comparative assessment and monitoring of deterioration of articulatory organs using subjective and objective tools among patients with amyotrophic lateral sclerosis.

Authors:  Wioletta Pawlukowska; Bartłomiej Baumert; Monika Gołąb-Janowska; Agnieszka Meller; Karolina Machowska-Sempruch; Agnieszka Wełnicka; Edyta Paczkowska; Iwona Rotter; Bogusław Machaliński; Przemysław Nowacki
Journal:  BMC Neurol       Date:  2019-10-19       Impact factor: 2.474

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.